Item List
What does positive clinical outcomes mean?
There are 3 types of positive clinical outcomes:
1. Stability of disease. This means the disease has stopped progressing. The symptoms have not worsened and is manageable. A person can live a long time at this stage with continued therapy.
2. Partial improvement. This means the disease has reduced or a malignant tumor has shrunk but did not disappear. The symptoms have improved, and body functions may have almost normalized.
3. No evidence of disease. This means the disease is no longer detected by conventional diagnostic study. There are no symptoms. Body function is normal. In essence the disease is in remission.
Is there any published research about RGCC testing?
Literature References for Validity, Precision, Accuracy, and Methodology of RGCC Testing
Liquid Biopsy Review Articles:
CTC Detection and Isolation using Negative Selection Method:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631028/ https://www.intechopen.com/chapters/51880 https://www.akadeum.com/technology/positive-selection-vs-negative-selection/?cn- reloaded=1 https://karger.com/cpb/article/40/3-4/411/74763/Evaluation-of-Isolation- Methods-for-Circulating https://www.cell.com/iscience/pdf/S2589-0042(22)00968-3.pdf
Chemosensitivity Assays using Liquid Biopsy of Melanoma CTCs:
https://rgcc-international.com/wp-content/uploads/2020/03/CTC-mel-BMC-2020.pdf
CTC Detection in Breast Cancer Patients:
https://rgcc-international.com/wp-content/uploads/2019/08/JCT_2019082714362025.pdf
CTC Analysis as Diagnostic Tool for Chemotherapy Response:
https://rgcc-international.com/wp-content/uploads/2019/06/Poster-2018-lisbon.pdf
CTCs to monitor disease progression and possible metastatic potential:
https://rgcc-international.com/wp-content/uploads/2019/06/Poster-2018-lisbon.pdf
Prediction of Metastases through study of CTCs:
https://rgcc-international.com/wp-content/uploads/2019/06/Risk-prediction-of-metastasis-through-study-of-circulating-tumor-cells.pdf
Review Article of Liquid Biopsy in Diagnosis and Prognosis of Colorectal Cancer:
https://lupinepublishers.com/cancer-journal/pdf/OAJOM.MS.ID.000199.pdf
Real-life Precision of Liquid Biopsy selecting drugs compared to Tissue Biopsy:
https://link.springer.com/content/pdf/10.1007/s00432-020-03156-3.pdf
Gene expression profiling that supports the Onco-D-Clare cancer screening test for healthy subjects: https://rgcc-international.com/wp-content/uploads/2019/06/Oncotarget.pdf
Study showing contribution of WBC gene expression in prediction of cancer (supporting the introduction of Onco-D-Clare cancer screening test for healthy subjects): https://rgcc-international.com/wp-content/uploads/2020/07/Binder1-abstract-1.pdf
Treatment based on Tumor Related Gene Expression:
Gene Expression analysis in CTCs with Colorectal Cancer compared with established protocols: https://rgcc-international.com/wp-content/uploads/2023/07/Poster-ESMO-GI-2023.pdf
Cell Culturing Assays:
Comparison of Cell Culturing Assays:
https://rgcc-international.com/wp-content/uploads/2019/07/JCT_2019072315145979.pdf
Click Here to read more on RGCC research publication.
What is the process of getting RGCC testing?
During the RGCC Test Order Consult Dr. Hickeywill initiate a request to RGCC North America distribution center in Atlanta, GA to drop ship a RGCC test kit to your home address (for North America residents only) via FedEx Ground. Delivery takes 4-8 days depending on location. The test kit contains a disposable blood draw kit, a vial containing EDTA to collect the blood sample, collection and shipping instructions and international paperwork (mostly pre-filled except your name, signature and date of blood draw), and a pre-paid FedEx International Priority shipping label. Blood draw service is either through AnyLabTestNow center (if available in your area) or via local mobile phlebotomy service. The test kit with the collected blood sample is taken to a local FedEx Store or hub to ship. Turn around time for test results averages 14-16 days. Results will be forwarded to you by Dr. Hickey.
What is RGCC Testing?
RGCC stands for Research Genetic Cancer Centre. It was founded by medical oncologist and genetics researcher, Dr. Ioannis Papasotiriou, MD, PhD in 2004. RGCC is an oncology research and development company that has 25+ branches in 20+ countries, and the global presence is increasing. RGCC headquarters is in Switzerland and general lab in Greece. There are other labs in Germany and India that are for research purposes.
RGCC testing is a molecular oncology blood test also known as “liquid biopsy” that detects whole cancer cells (circulating tumor cells) disseminated from primary and/or metastatic sites or from unknown primary sites at very low level, and enabling enumeration for the baseline, and for identification of the heterogeneous cancer cell population. The test is not meant to replace current conventional diagnostics, but like imaging and routine blood work it provides a more accurate assessment of the cancer status when combined with routine imaging study and routine blood labs.
An analogy comparing conventional diagnostics with RGCC testing is as follows. When doing clinical imaging studies (PET/CT, CT, MRI, US, Mammogram scans) of the body, on one hand it is like looking down at a forest from a drone high above and seeing the landscape and the borders or perimeters of an area of interest but unaware of what is happening at the ground level under the canopy of the trees. RGCC testing on the other hand is like looking from the roots of the trees up to the ground level to see what is happening. The view from the drone can spot changes in the topography, shape, borders, and perimeters of the forest indicating suspicious activity below, but a closer look down at the ground level and roots of the trees may reveal a different situation. Combining the two information produces an accurate assessment of the area of interest for baseline and future comparisons.
When making clinical decisions and creating therapy plans, an assessment or clinical impression of the disease condition needs to be as accurate as possible. Conventional oncology diagnostics have relied on technologies that have not matched the growing molecular oncology diagnostics until recent years. Around 2015, advances in molecular oncology diagnostics introduced “liquid biopsy”, which involves whole blood studies of circulating tumor DNA (ctDNA) from circulating tumor cells (CTC). Detecting ctDNA enables early cancer diagnosis for conventional oncology. The process of determining specific treatment plan is based on the biopsy-proven cancer diagnosis and what the FDA has approved for treatment of that diagnosis.
Unlike detecting ctDNA, RGCC testing detects the circulating tumor cells in the blood and includes chemosensitivity testing that determines what is or what are the most effective therapeutic anti-cancer agents (drugs or natural supplements) against the cancer cells in-vitro. So, rather than creating a specific treatment plan based on biopsy-proven diagnosis, RGCC testing enables creation of personalized integrative therapy plan based on the individual's cancer cell physiology. There is no need to guess what works when using RGCC testing. The testing also provides the information on CTC resistance to treatment factors and tumor related gene expression rates (mutated genes that support cancer proliferation) for further customization of personalize therapy. Currently 171 anti-cancer agents are tested routinely, and additional agents can be added to the blood sample for chemosensitivity testing at the discretion of the practitioner.
Integrating RGCC testing data with conventional oncology and holistic therapy enables maximum potential for positive clinical outcomes in oncology care.